Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page Bright Minds Biosciences Inc. (NASDAQ: DRUG) filing can feel like decoding neurochemistry itself. Trial data tables, at-the-market financing clauses, and receptor pharmacology footnotes are scattered across multiple forms—making it hard to spot what really moves the stock.
Stock Titan’s AI-powered analysis translates those complex disclosures into clear insights. Whether you need the Bright Minds Biosciences insider trading Form 4 transactions that hint at executive confidence, or the latest Bright Minds Biosciences quarterly earnings report 10-Q filing that details R&D burn and cash runway, our platform surfaces the numbers and context within seconds. Real-time feeds pull every 8-K material event, S-3 shelf registration, and 424B5 offering the moment they hit EDGAR—no manual refresh required.
Use our coverage to:
- Receive Bright Minds Biosciences Form 4 insider transactions real-time alerts and track executive stock transactions Form 4.
- Dive into a Bright Minds Biosciences annual report 10-K simplified summary that highlights clinical milestones, trial spend, and dilution risk.
- Quick-scan each 8-K with “Bright Minds Biosciences 8-K material events explained” tags that flag trial readouts or FDA feedback.
- Compare quarter-over-quarter spending with our Bright Minds Biosciences earnings report filing analysis.
- Understand governance details inside the Bright Minds Biosciences proxy statement executive compensation filing without digging through tables.
Whether you are understanding Bright Minds Biosciences SEC documents with AI for investment decisions or monitoring pipeline catalysts, Stock Titan delivers every filing—explained simply, updated instantly, and ready for action.
Janus Henderson Group plc and its affiliated Janus Henderson Biotech Innovation Master Fund Ltd report substantial beneficial holdings in Bright Minds Biosciences Inc. The parent reporting person discloses ownership of 1,145,660 shares representing 16.3% of the outstanding common stock, while the fund reports 984,485 shares or 14.0%. Both reporting persons indicate shared voting and dispositive power for their respective holdings and 0 shares of sole voting or dispositive power.
The filing identifies the reporting entities as institutional investors (designations include IA, HC for the parent and IV for the fund), notes that certain subsidiaries act as registered investment advisers, and includes a power-of-attorney authorizing compliance filings.
Bright Minds Biosciences' Schedule 13G/A shows Sio Capital Management, LLC beneficially owns 512,338 common shares, representing 7.27% of the outstanding class based on 7,043,989 shares disclosed by the issuer. Sio reports shared voting and shared dispositive power and no sole voting or dispositive power. Sio is a Delaware registered investment adviser to affiliated funds that directly hold the reported shares. A footnote states Sio GP, LLC and Michael Castor may be deemed to have influence, though that beneficial ownership is expressly disclaimed. The filer certifies the holdings are held in the ordinary course of business and not to change control.
Bright Minds Biosciences Inc. filed a Form 6-K attaching its Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 and its Management's Discussion and Analysis for the second quarter ended March 31, 2025. The filing lists Exhibits 99.1–99.4, including CEO and CFO certifications, and states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694). The report is signed by CFO Ryan Cheung and dated August 8, 2025.
FAQ
What is the current stock price of Bright Minds Biosciences (DRUG)?
What is the market cap of Bright Minds Biosciences (DRUG)?
